BACKGROUND: There is limited evidence from nationally representative samples about changes in prescription drug use for financial reasons among cancer survivors in the United States. METHODS: The 2011 to 2014 National Health Interview Survey was used to identify adults who reported ever having been told they had cancer (cancer survivors; n 5 8931) and individuals without a cancer history (n 5 126,287). Measures of changes in prescription drug use for financial reasons included: 1) skipping medication doses, 2) taking less medicine, 3) delaying filling a prescription, 4) asking a doctor for lower cost medication, 5) buying prescription drugs from another country, and 6) using alternative therapies. Multivariable logistic regression analyses were controlled for demographic characteristics, number of comorbid conditions, interactions between cancer history and number of comorbid conditions, and health insurance coverage. Main analyses were stratified by age (nonelderly, ages 18-64 years; elderly, ages 65 years) and time since diagnosis (recently diagnosed, <2 years; previously diagnosed, 2 years). RESULTS: Among nonelderly individuals, both recently diagnosed (31.6%) and previously diagnosed (27.9%) cancer survivors were more likely to report any change in prescription drug use for financial reasons than those without a cancer history (21.4%), with the excess percentage changes for individual measures ranging from 3.5% to 9.9% among previously diagnosed survivors and from 2.6% to 2.7% among recently diagnosed survivors (P < .01). Elderly cancer survivors and those without a cancer history had comparable rates of changes in prescription drug use for financial reasons. CONCLUSIONS: Nonelderly cancer survivors are particularly vulnerable to changes in prescription drug use for financial reasons, suggesting that targeted efforts are needed.
INTRODUCTION
The rising cost of cancer drugs imposes a significant financial burden on patients with cancer and their families. 1, 2 The direct medical cost of a new cancer medication per patient can routinely exceed $100,000 annually. 2, 3 Because of rising deductibles, copayments, coinsurance, and tiered drug formularies, an increasing portion of the cost of cancer drugs is shifted to the patient as out-of-pocket (OOP) costs. 4, 5 Previous studies demonstrated that cancer survivors faced significantly higher OOP costs than individuals without a cancer history. [6] [7] [8] The financial burden caused by the high OOP costs for cancer drugs may further impair cancer survivors' overall well being, adversely affect treatment choices and health outcomes, and result in higher medical expenditures in the long run. [9] [10] [11] [12] [13] Moreover, the increasing number of expensive, patient-administrated, oral antineoplastic agents may increase the likelihood that patients with cancer may delay, skip, or even forgo their prescription medications for financial reasons. [13] [14] [15] [16] A cancer diagnosis is associated with reduced adherence to recommended prescription drugs for other comorbid conditions, such as diabetes and cardiovascular disease, although, in some studies, it was unknown whether this was for financial reasons. [17] [18] [19] Previous studies demonstrating that patients with cancer make changes in prescription drug use to defray OOP costs are limited to small sample sizes, specific cancer sites, single-institutional experience, or trials without a noncancer control group. 11, [20] [21] [22] In the current study, we used nationally representative data to compare the changes in prescription drug use for financial reasons between cancer survivors and individuals without a cancer history. Because the intensity and aggressiveness of cancer-related treatments and associated costs are likely to be greater in nonelderly than in elderly patients and in those diagnosed in the most recent time period than in the past, [23] [24] [25] we stratified the analyses by age group and time since diagnosis. Moreover, we examined whether high private health insurance deductibles were associated with changes in prescription drug use for financial reasons among nonelderly cancer survivors. We also examined whether the pattern of changes in prescription drug use varies according to the number of comorbid conditions among cancer survivors.
MATERIALS AND METHODS

Data Sources
The National Health Interview Survey (NHIS) from 2011 through 2014 was used to identify cancer survivors and individuals without a cancer history. The NHIS is a cross-sectional household interview survey conducted annually by the Centers for Disease Control and Prevention's National Center for Health Statistics. It is a nationally representative survey of the civilian, noninstitutionalized population of the United States. The survey collects information on health status, access to and use of health care services, and comorbid conditions. The annual NHIS response rate ranged from 73.8% to 82% of eligible households during our study period. 26 
Individual-Level Characteristics and Analytic Sample
In the NHIS, cancer history is self-reported. We defined cancer survivors as those who reported ever having been told by a physician or other health professional that they had cancer or a malignancy of any kind. Cancer survivors who reported nonmelanoma skin cancer or skin cancer with unknown type were excluded. 27, 28 Individual-level demographic and clinical characteristics included, age at the time of the survey (nonelderly: ages 18-49 or 50-64 years; elderly: ages 65-74 or 75 years), sex, race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, or other), educational attainment ( high school graduate or some college), marital status (married or not married), geographic region (Northeast, Midwest, South, or West), health insurance coverage, and number of comorbid conditions (0, 1, 2, or 3). The health insurance coverage variable was defined differently for the 2 age groups (nonelderly: any private, other, or uninsured; elderly: Medicare with any private or other). Comorbid conditions included: arthritis, asthma, diabetes, emphysema, coronary heart disease, hypertension, stroke, angina pectoris, and heart attack. Time since diagnosis was calculated using age at cancer diagnosis and age at the time of the survey. We used 2 years as the cutoff point for categorizing those who were recently diagnosed and previously diagnosed to be consistent with previous studies. 7, 29 In the NHIS, private health insurance with an annual deductible >$1200 per individual or $2400 per family was categorized as a highdeductible plan. 26 An indicator for high insurance deductible status was created among nonelderly cancer survivors who had any private health insurance coverage during the survey year. The final sample was stratified by age group (nonelderly population, ages 18-64 years; elderly population, ages 65 years) and time since diagnosis (recently diagnosed, <2 years; previously diagnosed, 2 years), including recently diagnosed (nonelderly, n 5 686; elderly, n 5 720) and previously diagnosed (nonelderly, n 5 3295; elderly, n 5 4230) cancer survivors and individuals without a cancer history (nonelderly, n 5 76,096; elderly, n 5 16,989).
Measures of Changes in Prescription Drug Use for Financial Reasons
The NHIS included 6 measures of changes in prescription drug use for financial reasons. These are general questions about all prescriptions drugs and thus are not cancer specific. Respondents were asked the following questions: "During the past 12 months, were any of the following true for you: 1) you skipped medication doses to save money, 2) you took less medicine to save money, 3) you delayed filling a prescription to save money, 4) you asked your doctor for a lower cost medication to save money, 5) you bought prescription drugs from another country to save money, 6) you used alternative therapies to save money." A summary measure (yes/no) of any of the 6 measures and a categorical count of changes in prescription drug use for financial reasons (scored as 0, 1, or 2) also were also created.
Statistical Methods
We compared the distributions of individual-level characteristics between cancer survivors and those without a Original Article cancer history. We used multivariable logistic regression models for each of the 6 measures and the summary measure to estimate the changes in prescription drug use for financial reasons for both cancer survivors and individuals without a cancer history. Among nonelderly cancer survivors with private health insurance, we used multivariable logistic regressions to compare the patterns of changes in prescription drug use between high-deductible plans and low-deductible plans. We did not examine this association among the elderly cancer survivors because of their nearly universal eligibility for insurance through Medicare. Among all cancer survivors, multivariable ordered logistic regression was used to investigate associations between the number of comorbid conditions and changes in prescription drug use for financial reasons. Sensitivity analyses were conducted to examine the robustness of our findings by evaluating various summary measures based on a different reduced set of questions about changes in prescription drug use.
All multivariable regressions adjusted for survey year, age, race/ethnicity, sex, educational attainment, marital status, geographic region, health insurance coverage, the number of comorbid conditions, and interactions between cancer history and the number of comorbid conditions. The NHIS annual sampling weights were adjusted to reflect pooling data across multiple years and were used in all analyses to provide nationally representative estimates. 30 All adjusted estimates of changes in prescription drug use for financial reasons are presented as predictive margins. 31 All analytic files were created using SAS version 9.3. Multivariable logistic and ordered logistic regressions were performed using STATA 13.1. Statistical comparisons were 2-sided, and significance was defined as P < .05.
RESULTS
Distribution of Individual-Level Characteristics and Unadjusted Changes in Prescription Drug Use for Financial Reasons
Compared with individuals who had no history of cancer, cancer survivors were more likely to be older, nonHispanic white, married (nonelderly population only), and privately insured and to have more comorbid conditions (Table 1) . Nonelderly cancer survivors were more likely to be women, whereas elderly cancer survivors were more likely to be men compared with individuals who had no history of cancer. Among privately insured nonelderly cancer survivors, 41% of those who were recently diagnosed and 64% of those who were previously diagnosed enrolled in high-deductible plans. We also observed that both recently diagnosed and previously diagnosed nonelderly cancer survivors were more likely to report changes in prescription drug use for financial reasons than individuals without a history of cancer.
Adjusted Changes in Prescription Drug Use Between Cancer Survivors and Individuals Without a Cancer History
In the adjusted analyses, we observed that nonelderly cancer survivors were more likely to report changes in prescription drug use for financial reasons than nonelderly individuals without a cancer history (see Fig. 1 for total percentage changes and Table 2 for excess percentage changes). For the summary measure, 31.6% of recently diagnosed and 27.9% of previously diagnosed cancer survivors reported any change in prescription drug use for financial reasons, compared with 21.4% of individuals without a cancer history. The excess changes in prescription drug use for financial reasons associated with cancer were 10.2% (95% confidence interval [CI], 5.6%-14.8%) and 6.6% (95% CI, 4.4%-8.7%; all P < .05) for recently and previously diagnosed cancer survivors, respectively.
For individual measures among the nonelderly population, we observed that, compared with the control group: 1) 8.8% of previously diagnosed cancer survivors reported skipping medication doses (excess change, 2.7%; 95% CI, 1.4%-3.9%); 2) 9.9% of recently diagnosed and 9.3% of previously diagnosed cancer survivors reported taking less medicine (excess changes, 3.5% [95% CI, 0.3%-6.6%] and 2.8% [95% CI, 1.6%-4.1%], respectively); 3) 13.2% of recently diagnosed and 11.7% of previously diagnosed cancer survivors reported delaying filing a prescription (excess changes, 5.2% [95% CI, 1.4%-9.1%] and 3.7% [95% CI, 2.3%-5.1%], respectively); 4) 25.8% of recently diagnosed and 21.9% of previously diagnosed cancer survivors reported asking for lower cost medication (excess changes, 9.9% [95% CI, 5.6%-14.2%] and 6% [95% CI, 4.1%-7.9%], respectively); and 5) 7.4% of previously diagnosed cancer survivors reported using alternative therapies (excess change, 2.6%; 95% CI, 1.3%-3.8%; all P < .05).
Among the elderly population, we observed that, compared with the control group: 1) 22.6% of recently diagnosed cancer survivors reported asking for lower cost medication (excess change, 5% [95% CI, 1%-9.1%]; 2) on average, approximately 4% of previously diagnosed cancer survivors reported skipping medication doses, taking less medicine, and delaying filling a prescription (excess change, <1%) compared with individuals without a cancer history (all P < .05). Original Article The number of chronic conditions was defined as the sum of the following conditions that a respondent was ever told by a physician or other health professional that s/he had: arthritis, asthma, diabetes, emphysema, coronary heart disease, hypertension, stroke, angina pectoris, and heart attack. High cholesterol was not included because of the inconsistency of the availability of this variable across years.
e Among nonelderly cancer survivors who had any private health insurance during the survey year, 41% of those who were recently diagnosed and 64% of those who were previously diagnosed had highdeductible insurance plans.
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Cancer April 15, 2017 When the analyses were stratified by the number of comorbid conditions and compared with the control group (Supporting Table 1 ; see online supporting information), we observed that nonelderly cancer survivors were more likely to report changes in prescription drug use for financial reasons when the number of comorbid conditions was 1 for recently diagnosed patients and 2 for previously diagnosed patients (all P < .05). Elderly cancer survivors and those without a cancer history had comparable rates of changes in prescription drug use for financial reasons when stratified by the number of comorbid conditions.
Insurance Deductible Status and Adjusted Changes in Prescription Drug Use for Financial Reasons Among Nonelderly Cancer Survivors
Among privately insured nonelderly cancer survivors, 806 were enrolled in high-deductible plans, and 1399 enrolled in low-deductible plans (Fig. 2) . Compared with those enrolled in low-deductible plans (22.5%), nonelderly cancer survivors enrolled in high-deductible plans (32.2%) were more likely to ask their doctor for lower cost medication (odds ratio, 1.71; 95% CI, 1.32-2.22) (Supporting Table  2 ; see online supporting information).
Adjusted Changes in Prescription Drug Use by Number of Comorbid Conditions Among Cancer Survivors
We observed that, as the number of comorbid conditions increased from 0 to 3 (Fig. 3) : 1) the adjusted percentages of nonelderly cancer survivors increased from 24% to 51.2% for reporting any change and from 11.1% to 29.7% for reporting 2 or more changes in prescription drug use (all P < .001), respectively; 2) the adjusted percentages of elderly cancer survivors increased from 11.8% to 28.3% for reporting any change and from 2.6% to 7.5% for reporting 2 or more changes in prescription drug use (all P < .001), respectively. Time since diagnosis was not associated with the number of changes in prescription drug use that cancer survivors reported for financial reasons (Supporting Table 3 ; see online supporting information).
Sensitivity Analysis
Our findings of the summary measure were robust to various definitions that included different measures between cancer survivors and those without a cancer history (Supporting Table 4 ; see online supporting information).
DISCUSSION
Our study used a nationally representative sample to estimate patterns of changes in prescription drug use for financial reasons in both the nonelderly and elderly population of cancer survivors in the United States. We observed that both recently and previously diagnosed cancer survivors in the United States are more likely to alter their prescription drug use for financial reasons compared with individuals who do not have a history of cancer. This is particularly true in the nonelderly population. Moreover, nonelderly cancer survivors with high-deductible plans are more likely to ask for lower cost medication than those with low-deductible plans.
Nonelderly cancer survivors are particularly vulnerable to the risk of changing their prescription drug use for financial reasons, which may be explained in part by the complex relationship between employment and insurance coverage. A cancer diagnosis can result in barriers to working, productivity loss at work, reduced income, and employment disability. 7, 8, [32] [33] [34] The loss of employmentbased insurance coverage increases the likelihood of delaying and missing care because of cost. 35 Cancer survivors have been reported to have difficulties living within their household income, accrued debt, sold or refinanced their home, borrowed money from friends or family, or experienced a decline 20% in annual income because of treatment-related expenses. 9, 36 Our findings are consistent with the literature indicating that younger age is associated with increased risks of cancer-related financial problems and higher rates of personal bankruptcy because of medical bills. 9, 29, 32 Although elderly cancer survivors are likely to take more prescription drugs than elderly individuals without a history of cancer and may forgo expensive cancer drugs for financial reasons, we did not observe systematic differences in the probabilities of reporting changes in prescription drug use for financial reasons between them. This is Abbreviations: CI, confidence interval; OR, odds ratio. a All statistical tests were 2-sided, and all P values were derived from multivariable logistic regressions. All logistic regression analyses were controlled for survey year, age, sex, race/ethnicity, education, marital status, number of comorbid conditions, interactions between cancer history and number of comorbid conditions, health insurance status, and geographic region (Northeast, Midwest, South, and West). b P values reflect the statistical significance level of the changes in prescription drug use among cancer survivors versus individuals without a cancer history using multivariable logistic regression analysis. c All questions about changes in prescription drug use were asked for the last 12 months at the time of the survey. It was determined that the respondent was trying to save money if any of the items (skipped medication doses, took less medicine, delayed filing a prescription, asked doctor for lower cost medication, bought prescription drugs from another country, or used alternative therapies) were reported. d The survey question asks, "During the past 12 months, were any of the following true for you? . . .You skipped medication doses to save money."
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Cancer April 15, 2017 likely because of the near universal enrollment in Medicare, including prescription drug coverage for many, which may reduce the impact of medication cost on drug use. 23 Moreover, the measures of changes in prescription drug use include both cancer drugs and prescription drugs for other comorbid conditions. More than one-half of elderly individuals without a history of cancer had 2 or more comorbid conditions, which may also require prescription drugs. Although nonelderly and elderly populations are quite different in health status and financial situation, our results suggest that establishing programs that expand equitable access to care and prescription coverage in the nonelderly population can attenuate the financial burden of prescription drugs.
In the current study, we observed that the number of comorbid conditions was associated with changes in prescription drug use for financial reasons among cancer survivors. Others have reported that a new cancer diagnosis Blue areas represent the percentages of cancer survivors that had no change in prescription drug use; red areas, the percentages that had exactly 1 change in prescription drug use; green areas, the percentages that had at least 2 changes in prescription drug use.
was associated with nonadherence to prescription drugs for diabetes and cardiovascular disease, [17] [18] [19] which can have adverse consequences for the treatment of these conditions and may increase the risk of competing illnesses. Cancer is a life-threatening disease and may shift the focus of patients and providers from other comorbid conditions to cancer-related treatments. 37 In addition, the discontinuation of recommended prescription drugs for other comorbid conditions may result from a poor cancer prognosis, in which the risk of dying from cancer exceeds the risk of dying from other comorbid conditions. 19, 38 Our finding of an association between health insurance deductible status and asking physicians for lower cost medication among privately insured nonelderly cancer survivors is consistent with the research literature indicating that high OOP costs are associated with medication nonadherence. 13, 21, [39] [40] [41] [42] Future studies should monitor the changes in prescription drug use among cancer survivors, because several provisions of the Affordable Care Act (ACA) may play an important role in providing insurance coverage and reducing OOP costs. 43 Under the ACA, nonelderly cancer survivors will not be precluded from coverage because of preexisting conditions and will not lose coverage because of a cancer diagnosis. Elderly cancer survivors will benefit from the elimination of the coverage gap in Medicare Part D. Affordable health insurance plans through the Health Insurance Marketplace and tax credits toward reductions in OOP costs will also help cancer survivors reduce financial burden. Additional coverage through Medicaid expansion in certain states will also help low-income families lower the financial burden associated with cancer and its treatments. However, the extent to which the ACA can improve medication adherence among cancer survivors and whether total health care costs can be reduced because of improved treatment outcomes remain to be examined. 44, 45 Although we do not have information about whether these measures of changes in prescription drug use were specifically for cancer, our results from the summary measure were robust for the majority of cancer survivors in our sample when stratified according to the number of comorbid conditions. Therefore, our findings have implications for both oncologists and primary care physicians. The American Society of Clinical Oncology has identified patient-oncologist communication about cost as an important component of high-quality cancer care. 46 However, the majority of patients with cancer do not discuss costs with their providers despite their common concerns about the financial burden. 47, 48 Medical oncologists also need guidance about how to discuss costs with their patients, particularly when incremental costs are substantial but the marginal benefit is very small. 46, [49] [50] [51] Moreover, the increasing availability of expensive oral regimens may also require oncologists and patients to discuss the financial burden when making treatment decisions. 3, [52] [53] [54] [55] [56] Primary care physicians may want to consider the overall financial burden of prescription drugs among cancer survivors when coordinating care with oncologists, managing other comorbid conditions, and providing follow-up care to patients with cancer. 57, 58 Our study has several limitations. The cancer history was self-reported. However, previous studies indicated that medical records and self-reported cancer history are highly consistent. 59, 60 Time since diagnosis was measured by the difference between age at the time of the survey and age at cancer diagnosis, 7, 28, 61 which may have been subject to measurement error. Moreover, we did not have information on health insurance premiums, copayments, or coinsurance. Despite these limitations, our study used a nationally representative sample of adult cancer survivors, a comparison group without a history of cancer in both nonelderly and elderly populations, and detailed measures of health insurance stratified by age group. Our study provides a comprehensive analysis on the patterns of changes in prescription drug use at the national level and can be used to improve the quality of care among cancer survivors.
Conclusions
Compared with individuals without a cancer history, US cancer survivors face greater risks of changing their prescription drug use for financial reasons, particularly those aged <65 years. The patterns of changes in prescription drug use among cancer survivors vary by the number of comorbid conditions. Health care policies that help cancer survivors address the financial burden of prescription drugs should target those who have multiple comorbid conditions and high-deductible health plans.
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